Clinical Trial Details
| Trial ID: | L0530 |
| Source ID: | NCT03023748 |
| Associated Drug: | Intravenous Paricalcitol |
| Title: | Intravenous Paricalcitol in Chronic Hemodialysis Patients |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Endstage Renal Disease|Secondary Hyperparathyroidism |
| Interventions: | DRUG: Intravenous Paricalcitol |
| Outcome Measures: | Primary: Change in left ventricular mass index, MRI determined cardiac parameters, 52 weeks and 104 weeks | Secondary: Change in Coronary artery calcium score, Computed tomography determined coronary artery calcium score, 52 and 104 weeks|Change in Aortic stiffness, aortic pulse wave velocity, 52 and 104 weeks|Change in handgrip strength, nutrition and functional parameters, 52 and 104 weeks|Change in Serum albumin, Nutrition parameters, 52 and 104 weeks|Change in serum Calcium and phosphate, Biochemical parameters of CKD-MBD, 52 and 104 weeks|Change in Intact parathyroid hormone, Biochemical parameters of CKD-MBD, 52 and 104 weeks|Change in alkaline phosphatase, biochemical parameters of CKD-MBD, 52 and 104 weeks |
| Sponsor/Collaborators: | Sponsor: The University of Hong Kong | Collaborators: AbbVie |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 30 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2011-09 |
| Completion Date: | 2018-01 |
| Results First Posted: | |
| Last Update Posted: | 2017-01-18 |
| Locations: | Queen Mary Hospital and Tung Wah Hospital, Hong Kong, 0000, Hong Kong |
| URL: | https://clinicaltrials.gov/show/NCT03023748 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|